Higher Satisfaction With Switch to Triumeq from Existing ART, Study Finds

Higher Satisfaction With Switch to Triumeq from Existing ART, Study Finds
Higher Satisfaction With Switch to Triumeq from Existing ART, Study Finds

ViiV Healthcare announced new data from the Phase3b/4 STRIIVING study that evaluated the safety, efficacy, and tolerability of switching from an antiretroviral therapy (ART) to once-daily Triumeq (abacavir/dolutegravir/lamivudine) in virologically suppressed adults with HIV-1 infection (n=274).

STRIIVING was a randomized, open-label, multicenter study that enrolled patients switching from a range of ART that included protease inhibitor (n=234), integrase strand transfer inhibitor (n=146), and non-nucleoside reverse transcriptase inhibitor (n=171)-based regimens. The study met its primary endpoint in showing that viral suppression was non-inferior for patients switching to Triumeq (HIV RNA <50 copies/mL in intention to treat efficacy; n=551): 85% (Triumeq) vs. 88% (existing ART); and per protocol (n=435): 93% vs. 93%.

RELATED: For HIV+ Patients Who See Family Docs Exclusively, Experience is Key to Receiving ART

The study reported no patients with protocol defined virologic failure (HIV-1 RNA ≥400 copies/mL) and no patients were evaluated for treatment-emergent resistance in either study arm. Patients who switched to once-daily Triumeq also reported higher treatment satisfaction score improvements as measured by the HIV Treatment Satisfaction Questionnaire (adjusted difference 2.4; 95% CI: 1.3, 3.5; P<0.001).

Triumeq is a dolutegravir-based regimen that contains two nucleoside reverse transcriptase inhbiitors: abacavir and lamivudine. It is available as fixed-dose 600mg/50mg/300mg strength tablets in 30-count bottles.

For more information call (877) 356-8368 or visit Triumeq.com.

Loading links....